Literature DB >> 27867628

Radiosensitivity in the breast cancer management scenario: another step forward?

Icro Meattini1, Giulio Francolini1, Lorenzo Livi1.   

Abstract

Entities:  

Year:  2016        PMID： 27867628      PMCID： PMC5107524          DOI： 10.21037/jtd.2016.10.24

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  17 in total

1.  ARK5 suppresses the cell death induced by nutrient starvation and death receptors via inhibition of caspase 8 activation, but not by chemotherapeutic agents or UV irradiation.

Authors:  Atsushi Suzuki; Gen-Ichi Kusakai; Atsuhiro Kishimoto; Jie Lu; Tsutomu Ogura; Hiroyasu Esumi
Journal:  Oncogene       Date:  2003-09-18       Impact factor: 9.867

2.  Elective Nodal Irradiation in Breast Cancer: Time for Trials on the Basis of Tumor Biology.

Authors:  Lorenzo Livi; Icro Meattini; Orit Kaidar-Person; Philip M Poortmans
Journal:  J Clin Oncol       Date:  2016-05-23       Impact factor: 44.544

3.  Competing considerations in regional nodal treatment for early breast cancer.

Authors:  Boon Chua; Owen Ung; John Boyages
Journal:  Breast J       Date:  2002 Jan-Feb       Impact factor: 2.431

4.  Regional Nodal Irradiation in Early-Stage Breast Cancer.

Authors:  Timothy J Whelan; Ivo A Olivotto; Wendy R Parulekar; Ida Ackerman; Boon H Chua; Abdenour Nabid; Katherine A Vallis; Julia R White; Pierre Rousseau; Andre Fortin; Lori J Pierce; Lee Manchul; Susan Chafe; Maureen C Nolan; Peter Craighead; Julie Bowen; David R McCready; Kathleen I Pritchard; Karen Gelmon; Yvonne Murray; Judy-Anne W Chapman; Bingshu E Chen; Mark N Levine
Journal:  N Engl J Med       Date:  2015-07-23       Impact factor: 91.245

5.  Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer.

Authors:  Philip M Poortmans; Sandra Collette; Carine Kirkove; Erik Van Limbergen; Volker Budach; Henk Struikmans; Laurence Collette; Alain Fourquet; Philippe Maingon; Mariacarla Valli; Karin De Winter; Simone Marnitz; Isabelle Barillot; Luciano Scandolaro; Ernest Vonk; Carla Rodenhuis; Hugo Marsiglia; Nicola Weidner; Geertjan van Tienhoven; Christoph Glanzmann; Abraham Kuten; Rodrigo Arriagada; Harry Bartelink; Walter Van den Bogaert
Journal:  N Engl J Med       Date:  2015-07-23       Impact factor: 91.245

6.  Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.

Authors:  Viviana Galimberti; Bernard F Cole; Stefano Zurrida; Giuseppe Viale; Alberto Luini; Paolo Veronesi; Paola Baratella; Camelia Chifu; Manuela Sargenti; Mattia Intra; Oreste Gentilini; Mauro G Mastropasqua; Giovanni Mazzarol; Samuele Massarut; Jean-Rémi Garbay; Janez Zgajnar; Hanne Galatius; Angelo Recalcati; David Littlejohn; Monika Bamert; Marco Colleoni; Karen N Price; Meredith M Regan; Aron Goldhirsch; Alan S Coates; Richard D Gelber; Umberto Veronesi
Journal:  Lancet Oncol       Date:  2013-03-11       Impact factor: 41.316

7.  Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.

Authors:  Marianne Kyndi; Flemming B Sørensen; Helle Knudsen; Marie Overgaard; Hanne Melgaard Nielsen; Jens Overgaard
Journal:  J Clin Oncol       Date:  2008-02-19       Impact factor: 44.544

8.  Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy.

Authors:  Thomas A Buchholz; Eugene H Huang; Donald Berry; Lajos Pusztai; Eric A Strom; Marsha D McNeese; George H Perkins; Naomi R Schechter; Henry M Kuerer; Aman U Buzdar; Vicente Valero; Kelly K Hunt; Gabriel N Hortobagyi; Aysegul A Sahin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-08-01       Impact factor: 7.038

Review 9.  Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.

Authors:  S Darby; P McGale; C Correa; C Taylor; R Arriagada; M Clarke; D Cutter; C Davies; M Ewertz; J Godwin; R Gray; L Pierce; T Whelan; Y Wang; R Peto
Journal:  Lancet       Date:  2011-10-19       Impact factor: 79.321

10.  HER2 reduces breast cancer radiosensitivity by activating focal adhesion kinase in vitro and in vivo.

Authors:  Jing Hou; Zhirui Zhou; Xingxing Chen; Ruping Zhao; Zhaozhi Yang; Na Wei; Qing Ni; Yan Feng; Xiaoli Yu; Jinli Ma; Xiaomao Guo
Journal:  Oncotarget       Date:  2016-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.